ReviewFolia microbiologica2026
From mycelium to medicine: fungal strategies in the fight against resistance, cancer, and viral infections-insights from egyptian studies.
Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of antimicrobial resistance (AMR), alongside the global burden of cancer and viral infections, poses a major threat to human health and challenges existing therapeutic options. Multidrug-resistant pathogens, treatment failures in cancer, and emerging viral strains demand the urgent development of safer and more effective alternatives. Natural products, particularly fungal metabolites, have long been recognized as valuable sources of bioactive compounds with diverse pharmacological activities. Mushrooms, in particular, are rich in polysaccharides, terpenoids, flavonoids, phenolics, and other metabolites that exhibit antimicrobial, antiviral, antioxidant, immunomodulatory, and cytotoxic properties. Historical and modern evidence highlights their therapeutic potential against infections and malignancies, offering both preventive and curative benefits. In Egypt, where liver, breast, and colorectal cancers are highly prevalent, and AMR rates continue to rise, the search for novel natural agents is especially critical. Medicinal mushrooms such as Ganoderma lucidum, Lentinula edodes, Pleurotus spp., and Hericium erinaceus have demonstrated promising activities in vitro and in vivo, supporting their role as complementary or alternative therapies. Advances in extraction methods, from conventional hot water and solvent techniques to enzyme-assisted and supercritical fluid extraction, have further enhanced the recovery of potent fungal metabolites. This review summarizes the global and regional burden of AMR, cancer, and viral infections with particular emphasis on the Egyptian context, explores the bioactive potential of mushrooms, highlights key groups of fungal metabolites with therapeutic applications, and presents recent findings from Egyptian studies on locally sourced medicinal mushrooms. Harnessing these natural compounds offers a sustainable strategy for developing next-generation agents to overcome resistance, improve treatment outcomes, and support global health.
Indexed as
Identifiers
42507313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.